Profil bibliographique

Josephine Namusanje

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

14Publications signalées

387Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV-related health complications and treatmentsHIV Research and TreatmentBiological Research and Disease Studies

Publications récentes

Accès ouvert 2025 articleOpenAlex

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial

Lisanne A. H. Bevers, Gabriela Toledo, Muzamil Kisekka, Isabelle Déprez et autres

3 citationsEBioMedicine

Accès ouvert 2025 articleOpenAlex

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV

Lufina Tsirizani, Hylke Waalewijn, Alexander J. Szubert, Veronica Mulenga et autres

1 citationAntimicrobial Agents and Chemotherapy

Accès ouvert 2025 articleOpenAlex

Intracellular Penetration of Atazanavir, Ritonavir and Dolutegravir With Concomitant Rifampicin: A Dose Escalation Study

Amedeo De Nicolò, Alice Palermiti, Shamim Nakabuye, Josephine Namusanje et autres

2 citationsClinical Pharmacology & Therapeutics

Accès ouvert 2024 articleOpenAlex

Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial

Hylke Waalewijn, Roeland E. Wasmann, Alasdair Bamford, Diana M. Gibb et autres

2 citationsJournal of the Pediatric Infectious Diseases Society

Accès ouvert 2024 articleOpenAlex

Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa

Victor Riitho, Roisin Connon, Agnes Gwela, Josephine Namusanje et autres

15 citationsNature Communications

Accès ouvert 2023 articleOpenAlex

Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub‐study of the ODYSSEY randomized controlled trial

Linda Barlow‐Mosha, Grace Miriam Ahimbisibwe, Elizabeth Chappell, Pauline Amuge et autres

4 citationsJournal of the International AIDS Society

Accès ouvert 2023 articleOpenAlex

Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

Anna Turkova, Ellen White, Adeodata Kekitiinwa, Vivian Mumbiro et autres

11 citationsThe Lancet Child & Adolescent Health

Accès ouvert 2023 articleOpenAlex

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

Alexandra Compagnucci, Man K. Chan, Yacine Saïdi, Tim R. Cressey et autres

16 citationsEClinicalMedicine

Accès ouvert 2022 articleOpenAlex

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Pauline Amuge, Abbas Lugemwa, Ben Wynne, Hilda Mujuru et autres

33 citationsThe Lancet HIV

Accès ouvert 2022 articleOpenAlex

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Anna Turkova, Hylke Waalewijn, Man K. Chan, Pauline Bollen et autres

24 citationsThe Lancet HIV

Accès ouvert 2022 articleOpenAlex

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa et autres

142 citationsThe Lancet HIV

Accès ouvert 2018 articleOpenAlex

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

JA Thompson, Cissy Kityo, David Dunn, Anne Hoppé et autres

12 citationsClinical Infectious Diseases

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.